Drugs, Genentech | featured news

If you want the FDA to approve more innovative, new drugs based on promising but early clinical results, you have to give the FDA a way to revoke those approvals later on, should larger trials prove that those drugs aren't as safe or effective as they first seemed. This is why the FDA should be congratulated for the way it has handled the Avastin breast cancer saga, and why I hope we will see the FDA handle more cases like this one, not less.

Deal talks between Genentech and Roche hit a snag over dueling interpretations of arcane SEC rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.

Swiss drug company Roche Holding increased its offer to acquire the rest of Genentech to $93 a share from $86.50.